You are here

FDA Says More Drugs May Be Involved in Meningitis Outbreak

Another injectable steroid and a cardioplegic solution are implicated (Oct. 15)

As a result of ongoing investigations by the FDA, the Centers for Disease Control and Prevention (CDC), and state health departments of contamination at the New England Compounding Center’s (NECC) Framingham, Mass., facility, on October 4 the FDA advised providers not to use any NECC products. The company recalled all of its products on October 6.

Now, the FDA reports that a patient with possible meningitis potentially associated with epidural injection of an additional NECC product, triamcinolone acetonide, has been identified through active surveillance and has been reported to the agency. Triamcinolone acetonide is a type of steroid injectable product made by NECC. The cases of meningitis identified to date have been associated with methylprednisolone acetate, another similar steroid injectable product.

In addition, Aspergillus fumigatus infection has been reported in two transplant patients who were administered NECC cardioplegic solution during surgery. Investigation of these patients is ongoing, and there may be other explanations for their Aspergillus infection. Cardioplegic solution is used to induce cardiac muscle paralysis during open heart surgery to prevent injury to the heart.

The FDA continues to evaluate these reports and has not confirmed that the three infections were, in fact, caused by an NECC product.

In the agency’s opinion, the sterility of any injectable drugs, including ophthalmic drugs that are injectable or used in conjunction with eye surgery, and cardioplegic solutions produced by NECC is of significant concern, and patients who received these products should be alerted to the potential risk of infection. So far, no cases of infection have been reported to the FDA in connection with any NECC-produced ophthalmic drug that is injectable or used in conjunction with eye surgery, but the agency believes that this class of products could present similar risks of infection.

Source: FDA, October 15, 2012.

Recent Headlines

WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs